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In drug design, one way of improving metabolic stability is to introduce fluorine at a 
metabolically labile site.  At the early stages of drug design identification of such sites is 
challenging, and a rapid method of assessing the effect of fluorination on a putative drug’s 
metabolic stability would be of clear benefit.  One approach to this is to employ 
microorganisms that are established as models of drug metabolism in parallel with the 
synthesis of fluorinated drug analogues.  In this study we have used the filamentous fungus 
Cunninghamella elegans to identify the metabolically labile site of the non-steroidal anti-
inflammatory drug flurbiprofen, to aid in the design of fluorinated derivatives that were 
subsequently synthesised.  The effect of the additional fluorine substitution on cytochrome 
P450-catalysed oxidation was then determined via incubation with the fungus, and 
demonstrated that fluorine substitution at the 4’ position rendered the drug inactive to 
oxidative transformation, whereas substitution of fluorine at either 2’ or 3’ resulted in 
slower oxidation compared to the original drug. 
 Fluorine’s unique physicochemical properties, such as its size, electronegativity and 
strength of the carbon-fluorine bond, make it an important element in the design of drugs 
and other biologically active compounds.  Consequently, fluorine is present in approximately 
20 % of pharmaceuticals, including the blockbuster drugs Prozac and Lipitor, and 30 % of 
agrochemicals [1].  Owing to fluorine’s size, incorporation into biologically active compounds 
has only minor steric effects, but its high electronegativity leads to significant electronic 
consequences.  One reason for incorporating fluorine into drug molecules is to slow their 
metabolic processing though the cytochrome P450 (CYP)-mediated detoxification steps in 
the liver, thus extending their potency[2].  This requires knowledge of where the 
metabolically labile sites in the drug compound are, which is available for drugs that have 
already undergone ADME studies, and also increasingly for compounds that are at the very 
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early stage of development (hit-to-lead).    One approach to fluorinating metabolically labile 
sites is to activate the site via CYP-catalysed oxidation enabling further functionalization via 
deoxofluorination [3].  We have recently reported a straightforward chemical-microbial 
method for identifying metabolically sensitive sites on drug-like compounds, which can be 
fluorinated and then readily re-assessed for biotransformation[4].  By employing a 
microorganism, such as the zygomycete fungus Cunninghamella elegans or the 
actinomycete Streptomyces griseus, both of which express CYP and are known to metabolise 
drugs in a similar fashion to mammals[5], it was possible to identify the metabolically labile 
sites of drug-like biphenyl molecules.  Using Suzuki-Miyaura coupling reactions with relevant 
fluorinated benzene boronic acids, it was possible to generate fluorinated 
biphenylderivatives that, upon subsequent re-incubation with the microorganism, were 
stable to metabolic attack (Scheme 1). 
 In this paper we describe the next stage in the development of our technique, by 
demonstrating its applicability to a drug currently in use.  Flurbiprofen [(RS)-2-(2-fluoro-4-
biphenyl)propionic acid]1 is a non-steroidal anti-inflammatory drug used to manage arthritic 
pain, is an active ingredient in some throat lozenges and the R-enantiomer is in clinical trials 
as a treatment of prostate cancer[6].  When incubated with C. elegans and S. griseus 
flurbiprofen is transformed to the main human metabolite, 4’-hydroxy-flurbiprofen2, and to 
the minor metabolites 3’, 4’-dihydroxyflurbiprofen 3and 3’hydroxy, 4’methoxy-
flurbiprofen4[7](Scheme 2); in C. elegans a sulfated conjugated metabolite is also generated.  
Therefore, in this paper we report the synthesis of various fluorinated derivatives of 
flurbiprofen5-9, which were subsequently incubated with C. elegans, so that the effect of 
fluorine substitution on metabolically labile sites could be evaluated. 
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A short series of flurbiprofen analogues 5-9was synthesised by a 5-step strategy, 
adapting literature procedures [8](Scheme 3).  Reaction of diethyl 2-methyl malonate ester 
with 2,4-difluoronitrobenzene 10 mediated by sodium hydride proceeded in high yield to 
give desired product 11 (97%) arising from nucleophilic substitution of fluorine para to the 
nitro substituent.  Small quantities of product arising from competing ortho-substitution 
were detected by 19F NMR but the isomeric mixture was used in the following stages 
without purification.  Hydrogenation of the nitro group of 11 to give corresponding aniline 
12 was accomplished by reaction with hydrogen over a palladium-on-carbon catalyst and 
subsequent diazotisation-iodination gave the key iodoaromatic intermediate 13 in good 
yield.  Palladium-catalysed Suzuki-Miyaura coupling reactions between iodoaromatic 13 and 
a range of fluoroaryl boronic acids 14a-f gave corresponding biphenyl diesters 15a-f.  
Subsequent decarboxylation and hydrolysis gave a short series of the desired fluorinated 
flurbiprofen analogues5-9.  Recrystallisation of the acid analogues removed trace quantities 
of ortho substituted products carried through the synthesis from the first stage and, for 
example, the structure of 7 was confirmed by X-ray crystallography (Fig. 1). 
 The fluorinated flurbiprofen analogues5-9(0.1 mg/ml) were incubated with C. 
elegans as we described previously[4].Briefly, the fungus was cultivated for 72 h in 250 ml 
Erlenmeyer flasks containing 45 ml sabouraud dextrose broth prior to the addition of the 
drug.  After further 72 h incubation, the culture was extracted with ethyl acetate and the 
solvent removed under reduced pressure.  The oxidation products were analysed by gas 
chromatography-mass spectrometry after silylation with N-methyl-N-(trimethylsilyl) 
trifluoroacetamide (MSTFA).  Only the starting compounds5, 8 and 9were detected after 
incubation.  The absence of transformation was expected based on the knowledge that CYP-
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catalysed hydroxylation occurs at the 4’-position of flurbiprofen, and is consistent with our 
previous observations concerning metabolism of model fluorinated biphenyl 
derivatives,[4]and confirms the effectiveness of this methodology for identifying metabolic 
labile sites for fluorinated drug design. 
2’-Fluoro- and 3’-fluoro-flurbiprofen were transformed in varying degrees by the 
fungus (Fig 2).  3’-Fluoro-flurbiprofen6 was almost entirely converted to a single 
hydroxylated product as observed by GC-MS analysis whereas 2’-fluoro-flurobiprofen 7was 
incompletely transformed (approx. 30 % starting material remained) yielding three products 
all with the expected mass of corresponding hydroxylated derivatives.  
 To identify whether any products are formed by incubation of 6 and 7 with C. 
elegans and to aid oxidation products identification,19F NMR analysis of the extracts was 
conducted and, as expected, one fluorinated product was observed from the extracts 
recovered from incubation with 6 and three products from 7(Fig. 3).   
 19F NMR substituent chemical shift (SCS) analysis can be used to identify the 
hydroxylated products arising from oxidation of 6 and 7 by C. elegans. Peelen et al. [9] 
conducted extensive 19F NMR experiments when investigating enzymatic hydroxylation of 
fluorophenol, and demonstrated that hydroxylations ortho, meta and para to the fluorine 
resulted in substituent shifts from the starting substrate of -23, +1.3 and -11 ppm, 
respectively, upon substitution of hydrogen atom by a hydroxyl group. Consequently, simple 
calculations allow a reasonable prediction of 19F NMR chemical shifts for all possible 
hydroxylated products (Fig. 4). 
 Using the data in Figs. 3 and 4, it is reasonable to conclude that 3’-fluoro-flurbiprofen 
6 is most probably converted to the 4’-hydroxylated product 10a, consistent with our earlier 
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findings concerning metabolism of model biphenyl derivatives at the 4’-position [4] although 
10b is a possible product based upon the 19F NMR shift.  In contrast, 2’-fluoro-flurbiprofen 
7 gives three hydroxylated products by GC-MS and 19F NMR analysis, the main product 
probably being 11b arising from hydroxylation of the 4’-position consistent with earlier 
findings [4] with minor products 11a and 11c, in the approximate ratio 11a : 11b : 11c  1 : 8 : 
2 by 19F NMR resonance intensities. Again the major product is most probably hydroxylation 
at the least metabolically stable 4’-position 11b although significant quantities of 11a and 
11c are formed reflecting the stabilising effect of fluorine ortho and para to the sites of 
oxidation. 
 To demonstrate that the fungus is an appropriate model for metabolic stability 
experiments, rat-liver microsomes [10] were incubated with the flurbiprofen derivatives 5-8, 
plus NADPH.  The same transformation products were detected by GC-MS from 6 and 7; in 
contrast, no transformation of 5 and 8 was observed confirming that blocking the 4’ position 
with fluorine prevented metabolism. 
 In summary, following our previously reported strategy for identifying metabolically 
labile sites on drug-like compounds for subsequent fluorination, we have demonstrated that 
this strategy is effective for generating fluorinated derivatives of known drugs that are 
metabolically stabilised.  Flurbiprofen 1 is known to be initially oxidised at the 4’ position by 
both mammals and microorganisms. Analogues of flurbiprofen bearing fluorine atoms at the 
2’-, 3’- and 4’-positions 5-7were synthesised.  Upon incubation with C. elegans to determine 
if these modifications had any effect on biotransformation, the flurbiprofen analogue that 
had an additional fluorine in the 4’ position 7 was completely stable to metabolism.  
Analogues of the parent drug with fluorine located at the 2’ and 3’ positions resulted in 
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hydroxylation to varying degrees upon incubation; 3’fluoroflurbiprofen 6 was almost 
completely transformed to a hydroxylated product 10a whereas 2’fluoroflurbiprofen 7 was 
transformed to a lesser extent, and to three mono-hydroxylated products.  Significantly, the 
same transformation products were detected after rat liver microsomes were incubated 
with 5-8, demonstrating the relevance of the microbial model used here.  It is often 
attractive to improve drug efficacy by slowing their metabolism, thus 2’- and 3’-
fluoroflurbiprofen might be more useful derivatives as their biotransformation is altered, 
but not completely prevented, as with the 4’ fluorinated analogue. 
 
Experimental Section 
Details of the synthetic procedures, characterisation of compounds and microbiological 
methods can be found in the Supplemental Information. 
 
Acknowledgements 
This work was supported in part by a Royal Society International Project Grant, Durham 
University M.Chem Programme and UCD Research Demonstrator Scheme. We thank Dr D.S. 
Yufit for X-ray crystallography. 
 
Keywords: Cross-coupling, cytochromes, drug design, fluorine, metabolism 
 
References 
8 
 
[1] a) C. Isanbor, D. O'Hagan, Journal of Fluorine Chemistry 2006, 127, 303-319; b) K. L. Kirk, 
Journal of Fluorine Chemistry 2006, 127, 1013-1029; c) K. Muller, C. Faeh, F. Diederich, 
Science 2007, 317, 1881-1886. 
[2] S. Purser, P. R. Moore, S. Swallow, V. Gouverneur, Chem. Soc. Rev. 2008, 37, 320-330. 
[3] a) A. Rentmeister, F. H. Arnold, R. Fasan, Nature Chemical Biology 2009, 5, 26-28; b) K. 
Zhang, B. M. Shafer, M. D. Demars, H. A. Stern, R. Fasan, Journal of the American Chemical 
Society 2012, 134, 18695-18704. 
[4] T. V. Bright, F. Dalton, V. L. Elder, C. D. Murphy, N. K. O'Connor, G. Sandford, Organic & 
Biomolecular Chemistry 2013, 11, 1135-1142. 
[5] a) S. Asha, M. Vidyavathi, Biotechnol. Adv. 2009, 27, 16-29; b) D. C. Lamb, M. R. Waterman, 
B. Zhao, Expert Opinion on Drug Metabolism & Toxicology 2013, 9, 1279-1294. 
[6] a) L. Perioli, V. Ambrogi, S. Giovagnoli, M. Ricci, P. Blasi, C. Rossi, AAPS PharmSciTech 2007, 
8; b) E. J. Quann, F. Khwaja, K. H. Zavitz, D. Djakiew, Cancer Res. 2007, 67, 3254-3262. 
[7] a) J. Amadio, K. Gordon, C. D. Murphy, Applied and Environmental Microbiology 2010, 76, 
6299-6303; b) T. V. Bright, B. R. Clark, E. O'Brien, C. D. Murphy, J. Mol. Catal. B-Enzym. 2011, 
72, 116-121. 
[8] I. Peretto, S. Radaelli, C. Parini, M. Zandi, L. F. Raveglia, G. Dondio, L. Fontanella, P. Misiano, 
C. Bigogno, A. Rizzi, B. Riccardi, M. Biscaioli, S. Marchetti, P. Puccini, S. Catinella, I. Rondelli, 
V. Cenacchi, P. T. Bolzoni, P. Caruso, G. Villetti, F. Facchinetti, E. Del Giudice, N. Moretto, B. 
P. Imbimbo, J. Med. Chem. 2005, 48, 5705-5720. 
[9] S. Peelen, I. Rietjens, M. G. Boersma, J. Vervoort, European Journal of Biochemistry 1995, 
227, 284-291. 
[10] R. S. Obach, Drug Metabolism and Disposition 1999, 27, 1350-1359. 
 
Scheme and Figure Legends 
Scheme 1.  A chemical-microbial method for developing metabolically stable fluorinated 
drug-like molecules [3]. 
Scheme 2.  Oxidative metabolites of flurbiprofen via incubation with C. elegans and S. 
griseus. 
Scheme 3. Synthesis of fluorinated Flurbiprofen analogues5-9 
Figure 1. Molecular structure of 7 
Figure 2.  Total ion chromatograms from incubation of 6 and 7 with C. elegans: A, 6 without 
fungus; B, biotransformation of 6 to hydroxylated product; C, 7 without fungus; 
biotransformation of 7 to three hydroxylated products.  All of the extracts were derivatised 
with MSTFA prior to GC-MS analysis. 
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Figure 3.  F-19 NMR spectra of extracts from C. elegans cultures incubated with 3’-fluoroflurbiprofen 
6 (top) and 2’fluoroflurbiprofen 7(bottom). 
Figure 4. Calculated and observed 19F NMR shifts of hydroxylated flurbiprofen derivatives 10 
and 11 
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